Off‐label use of dupilumab in the management of pediatric urticaria vasculitis: A promising therapeutic choice

Documenti analoghi

• An overview on current practices regarding the diagnosis and management of chronic urticaria in pediatrics: An EAACI Task Force report
  di: Stefania Arasi, et al.
  Pubblicazione: (2025)
• Unveiling a suspected dupilumab‐induced neuropathy in pediatric eosinophilic esophagitis
  di: Hugo Gagnon, et al.
  Pubblicazione: (2024)
• Editorial comment on “An overview on current practices regarding the diagnosis and management of chronic urticaria in pediatrics: An EAACI Task Force report”
  di: Polina Pyatilova, et al.
  Pubblicazione: (2025)
• Use of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity
  di: Paola Zangari, et al.
  Pubblicazione: (2024)
• Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?
  di: Güler Yıldırım, et al.
  Pubblicazione: (2025)